Reimbursement begins slowly for Biogen’s expensive Alzheimer’s drug
Medicare Administrative Contractors, or MACs, are now sporadically reimbursing for Biogen’s expensive new Alzheimer’s drug in limited pockets across the US, as CMS has several months left to finish its decision on national coverage.
The slow trickle of MAC coverage, which one senior Biogen employee told Endpoints News is “regional at best,” comes as there’s been “no uptick in usage thus far,” continuing the slow rollout following FDA’s accelerated approval in June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.